8-K: Vivani Medical Prioritizes Obesity Treatment with Promising GLP-1 Implant Data and $15 Million Financing

Vivani Medical shifts strategic focus to obesity treatment, reports positive preclinical data for its GLP-1 implant, and secures $15 million in funding to accelerate development programs.

Summary

• Vivani Medical is prioritizing the development of GLP-1 implants for obesity and chronic weight management.
• The company's lead program, NPM-115, a six-month exenatide implant, has shown preclinical weight loss data comparable to semaglutide, the active ingredient in Ozempic and Wegovy.
• Vivani also disclosed semaglutide as the active ingredient in NPM-139, a once-yearly subdermal GLP-1 implant for chronic weight management.
• A recent $15 million financing round will support the acceleration of priority development programs and fund operations into the second half of 2025.
• The company is on track to submit a new Investigational New Drug Application for NPM-115 later this year.
• Vivani is also working to provide the FDA with requested information for NPM-119, aiming for clinical development clearance.
• Vivani's cash balance was $22.0 million as of December 31, 2023, down from $46.4 million the previous year.
• The net loss for the full year 2023 was $25.7 million, compared to $13.9 million in 2022.
• Research and development expenses for 2023 were $17.0 million, up from $14.2 million in 2022.
• General and administrative expenses for 2023 were $10.0 million, compared to $7.1 million in 2022.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive developments in the pipeline and a successful capital raise, the increased losses and clinical hold on NPM-119 temper the overall sentiment. The strategic shift to obesity is positive, but the company faces significant challenges.

Positives

• Vivani's strategic shift to focus on obesity treatments is promising given the large market opportunity.
• The preclinical data for NPM-115 showing comparable weight loss to semaglutide is a significant positive.
• The $15 million financing provides runway into the second half of 2025, allowing for continued development.
• The company is on track to submit an IND for NPM-115 later this year.
• The appointment of Daniel Bradbury to the Board of Directors brings valuable experience in the GLP-1 space.
• The company has moved into a dedicated facility capable of supporting large-scale clinical trial material manufacturing.

Negatives

• The company experienced a significant decrease in cash balance from $46.4 million to $22.0 million year-over-year.
• The net loss increased from $13.9 million in 2022 to $25.7 million in 2023.
• There is a current clinical hold on NPM-119, requiring additional CMC information to be submitted to the FDA.
• The company has a history of losses and needs to achieve profitability in the future.
• The company is dependent on third parties for some aspects of manufacturing, research and testing.

Risks

• The development and commercialization of product candidates, including NPM-115 and NPM-119, carries inherent risks.
• Delays in submitting required regulatory applications to the FDA could impact timelines.
• There are risks related to the initiation, enrollment, and conduct of planned clinical trials.
• The company has a history of losses and may not achieve or sustain profitability.
• The company is dependent on third parties for some aspects of manufacturing, research and testing.
• The company may fail to secure marketing approvals for its products.
• There may be delays in regulatory approval or changes in regulatory framework that are out of the company's control.
• The company's estimation of addressable markets of its products may be inaccurate.
• The company may fail to timely raise additional required funding.
• More efficient competitors or more effective competing treatments may emerge.
• The company may be involved in disputes surrounding the use of its intellectual property.
• The company may not be able to attract and retain key employees and qualified personnel.
• Earlier study results may not be predictive of later stage study outcomes.

Future Outlook

Vivani anticipates filing the NPM-115 Investigational New Drug Application in the second half of 2024 and initiating a first-in-human trial after receiving regulatory clearance. The company also anticipates filing a Complete Response to the current Clinical Hold on NPM-119 during the first half of 2024.

Management Comments

• Adam Mendelsohn, Ph.D., Vivanis Chief Executive Officer, stated, 2023 was another remarkable year for Vivani as we shifted our strategic focus to our obesity portfolio and announced that our lead program NPM-115 a six-month GLP-1 implant for obesity generated preclinical weight loss data comparable to semaglutide, the active ingredient in Ozempic and Wegovy.
• Dr. Mendelsohn added, We are on track to submit a new Investigational New Drug Application for NPM-115, our high-dose exenatide implant for chronic weight management in obese and overweight patients with one or more risk factors, later this year.

Industry Context

The announcement aligns with the growing interest and investment in GLP-1 therapies for obesity and diabetes. The company is positioning itself to compete in a market dominated by large pharmaceutical companies by focusing on long-term implantable drug delivery systems.

Comparison to Industry Standards

• The preclinical weight loss data for NPM-115 is compared to semaglutide, the active ingredient in Ozempic and Wegovy, which are blockbuster drugs in the GLP-1 market.
• The company references Intarcia's ITCA-650, a long-term exenatide implant, as a relevant value analog, highlighting the potential of long-term drug delivery systems.
• The document notes that the GLP-1 market is estimated to reach $71 billion by 2032, indicating the significant market opportunity Vivani is targeting.
• The company's focus on improving medication adherence addresses a key challenge in chronic disease management, where approximately 50% of patients do not take their medication as prescribed.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the $15 million capital raise and the company's financial performance.
• Employees will be impacted by the company's strategic shift and the move to a new facility.
• Patients with obesity and type 2 diabetes could benefit from the development of new long-term drug implants.
• Creditors will be impacted by the company's financial performance and ability to repay debts.
• Suppliers will be impacted by the company's manufacturing and research activities.

Next Steps

• Vivani anticipates filing the NPM-115 Investigational New Drug Application in the second half of 2024.
• The company plans to initiate a first-in-human trial for NPM-115 after receiving regulatory clearance.
• Vivani anticipates filing a Complete Response to the current Clinical Hold on NPM-119 during the first half of 2024.
• The company is seeking SEC approval to proceed with an initial public offering for wholly owned subsidiary Cortigent, Inc.

Key Dates

Keywords

GLP-1, obesity, weight management, exenatide, semaglutide, implant, NPM-115, NPM-119, clinical trials, drug delivery, biopharmaceutical, NanoPortal, FDA, financing